Home / Biotech/Pharma / NeuroDerm Files for a Proposed $65M NASDAQ IPO
Photo credit: Lending Memo, https://flic.kr/p/jco6RG, License: https://creativecommons.org/licenses/by/2.0/legalcode

NeuroDerm Files for a Proposed $65M NASDAQ IPO נוירודרם הגיש תשקיף לגיוס של כ-65 מיליון דולרים בנאסד"ק

Following the trend of Israeli biotechs going public, Rehovot-based NeuroDerm has filed with the SEC to raise $65 million in an initial public offering. The company plans to list on the NASDAQ under the ticker symbol ‘NDRM’.

Jefferies LLC and Cowen & Company, LLC are the joint bookrunners on the deal. No pricing terms have yet been disclosed. News of the filing has come within only a month of the company’s latest financing round of $16 million.

NeuroDerm is a clinical-stage pharmaceutical company developing formulations and new administration methods to treat moderate to severe Parkinson’s disease. The company has developed a line of levodopa/carbidopa product candidates administered through small belt pumps that deliver a continuous, controlled dose of drug. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot.

Read the SEC Filing.

Read about the IPO filing in Hebrew at Globes.

Comments

comments

About bio972

Leave a Reply